Overview

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase:

Phase 2

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab